This paper investigates a model of oncolytic virotherapy formulated as a triply haptotactic cross-diffusion system 0.1 \(\begin{aligned} \left\{ \begin{aligned}&u_t=D_u \Delta u-\xi _u\nabla \cdot (u\nabla v)+\mu _uu(1-u)-\rho _u uz,&\quad&x\in \Omega ,t>0,\\&v_t=-(\alpha _u u+\alpha _w h(w))v+\mu _v v(1-v),&\quad&x\in \Omega ,t>0,\\&w_t=D_w \Delta w-\xi _w\nabla \cdot (w\nabla v)-\delta _w w+\rho _w uz,&\quad&x\in \Omega ,t>0,\\&z_t=D_z \Delta z-\xi _z\nabla \cdot (z\nabla v)-\delta _z z-\rho _z uz+\beta w,&\quad&x\in \Omega ,t>0,\\&\qquad \quad (D_u \nabla u-\xi _u u\nabla v)\cdot \nu =(D_w \nabla w-\xi _w w\nabla v)\cdot \nu =(D_z\nabla z-\xi _z z\nabla v)\cdot \nu =0,&\quad&x\in \partial \Omega ,t>0,\\&u(x,0)=u_0(x),\,\,v(x,0)=v_0(x),\,\,w(x,0)=w_0(x),\,\,z(x,0)=z_0(x),&\quad&x\in \Omega , \end{aligned} \right. \end{aligned}\) in a bounded domain \(\Omega \subset \mathbb {R}^N\) ( \(N\ge 3\) is the dimension of sapce) with smooth boundary, where \(h\in C^{2}([0,\infty ))\) satisfies \(0\le h(s)\le K_ws^{k_w}\) for all \(s\ge 0\) with some \(K_w>0\) and \(k_w>0\) . We demonstrate that whenever \(D_u\mu _u>\frac{N-2}{N}\xi _u\alpha _u\max \{1,\Vert v_0\Vert _{L^\infty (\Omega )}\}\) and \(0<k_w<\frac{2}{N}\) , the system admits a globally bounded solution satisfying that \(\begin{aligned} \Vert u(\cdot ,t)\Vert _{L^\infty (\Omega )}+\Vert v(\cdot ,t)\Vert _{L^\infty (\Omega )}+\Vert w(\cdot ,t)\Vert _{L^\infty (\Omega )}+\Vert z(\cdot ,t)\Vert _{L^\infty (\Omega )}\le C \end{aligned}\) for all \(t>0\) with some constant \(C>0\) . To our knowledge, this constitutes the most recent advancement in the triply haptotactic cross-diffusion model in three-dimensional or higher-dimensional spaces.